Publications
Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38695832
Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38695832
Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38695832
Laura Huppert, Lindy Her, Christine Hodgdon, Susie Brain, Carol Simmons, Jo Chien, Melanie Majure, Hope Rugo, Mark Jesus Magbanua, Ron Balassanian, Michelle Melisko. Abstract PS11-03: Comparison of next-generation sequencing (NGS) results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer (MBC) and leptomeningeal disease (LMD). Cancer research. 2024. PMID:
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38754471
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38754467
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL, International Myeloma Working Group. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The Lancet. Oncology. 2024. PMID: 38697166
Liu VN, Van Blarigan EL, Zhang L, Graff RE, Loeb S, Langlais CS, Cowan JE, Carroll PR, Chan JM, Kenfield SA. Plant-Based Diets and Disease Progression in Men With Prostate Cancer. JAMA network open. 2024. PMID: 38691361
Koshkin VS. Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer. JAMA network open. 2024. PMID: 38696174
Litt HK, Greenstreet-Akman E, Trejo E, Florez N, Velazquez AI. Quality and Accessibility of Liquid Biopsy Information. JAMA network open. 2024. PMID: 38713467
Kaplan LD. Corrigendum to "HIV-associated lymphoma" [Best Pract Res Clin Haematol 25 (2012) 101-117]. Volume 37 of Issue 2 Best practice & research. Clinical haematology. 2024. PMID: 39098802
Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA: a cancer journal for clinicians. 2024. PMID: 38685134
Reyes KR, Wong P, Petrofsky M, Dai A, Pelayo A, Brondfield S, Kwon DH. Shared decision-making needs, barriers, and facilitators of patients with newly diagnosed advanced cancer in the hospital: a multi-level, mixed-methods study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2024. PMID: 38684522
Reyes KR, Wong P, Petrofsky M, Dai A, Pelayo A, Brondfield S, Kwon DH. Shared decision-making needs, barriers, and facilitators of patients with newly diagnosed advanced cancer in the hospital: a multi-level, mixed-methods study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2024. PMID: 38684522
Oppegaard KR, Mayo SJ, Armstrong TS, Dokiparthi V, Melisko M, Levine JD, Olshen AB, Anguera JA, Roy R, Paul S, Cooper B, Conley YP, Hammer MJ, Miaskowski C, Kober KM. Neurodegenerative disease pathways are perturbed in patients with cancer who self-report cognitive changes and anxiety: A pathway impact analysis. Cancer. 2024. PMID: 38676932
Spinner MA, Advani RH. Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium. Expert opinion on emerging drugs. 2024. PMID: 38676917
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ breast cancer. 2024. PMID: 38671001
Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer. 2024. PMID: 38664404
Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO oncology practice. 2024. PMID: 38662970
Duvalyan E, Brondfield S, Rushakoff RJ, Anderson MS, Quandt Z. Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study. Cancers. 2024. PMID: 38730614